Cost-benefit and cost-effectiveness analysis of the rapid onset of selective serotonin reuptake inhibitors by augmentation

International Journal of Psychiatry in Medicine

Volumn 27, Issue 4, 1997, Pages 377-390

  Tome, Maria B ^a,b   Isaac, Michael T ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY HOSPITAL LEWISHAM   (United Kingdom)

Author keywords

Antidepressants; Augmentation; Cost effectiveness; Depression; Pharmacy; Quality of life; Randomized controlled trial; SSRI

Indexed keywords

PLACEBO; SEROTONIN 1A ANTAGONIST; SEROTONIN UPTAKE INHIBITOR;

ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; DEPRESSION; DOUBLE BLIND PROCEDURE; DRUG COST; HUMAN; MAJOR CLINICAL STUDY; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; UNITED KINGDOM; UNITED STATES;

EID: 0031419140     PISSN: 00912174     EISSN: None     Source Type: Journal    
DOI: 10.2190/6T1E-A6E1-V2J6-JL99     Document Type: Article

References (18)

1. Tomé M, Isaac M, Harte R, Holland C. Paroxetine and pindolol: A randomised trial of serotonergic autoreceptor blockade in the reduction of antidepressant latency. International Clinical Psychopharmacology 1997;12:81-89.
2. Russell LB, Gold MR, Siegel JE, Daniels N, Weinstein MC. The role of cost-effectiveness analysis in health and medicine. Journal American Medical Association 1996;276:1172-1177.
3. Drummond MF. Principles of economic appraisal in health care. Oxford, England: Oxford Medical Publications, 1980.
4. Johannesson M, Weinstein MC. Designing and conducting cost-benefit analyses. Quality of life pharmacoeconomics in clinical trials. 2nd Edition. Spilker B, editor. Philadelphia: Lippincott-Raven Publishers, 1996;1085-1092.
5. Weinstein MC, Fineberg HV. Clinical decision analysis. (WB Saunders Company, Philadelphia USA).
6. Kind P, Sorensen J. Modelling the cost-effectiveness of the prophylactic use of SSRIs in the treatment of depression. International Clinical Psychopharmacology 1995; 1(10Suppl.):41-48.
7. West R. Depression. London, England: Office of Health Economics, 1992.
8. Greenberg PE, Stiglin LE, Finkelstein SN, Berndt ER. The economic burden of depression. Journal of Clinical Psychiatry 1993;54:405-418.
9. Snaith RP, Harrop FM, Newby DA, Teale C. Grade scores of the Montgomery-Åsberg Depression and the Clinical Anxiety scales. British Journal of Psychiatry 1986; 148:599-601.
10. British Medical Association and the Royal Pharmaceutical Society of Great Britain. British National Formulary, Number 31, March 1996. London, England.
11. Jönsson B, Bebbington P. Economic studies of the treatment of depressive illness. In: Health economics of depression. Jönsson B and Rosenbaum J, editors. Chichester and New York: John Wiley & Sons,1993:35-48.
12. Begg D, Fisher S, Dornbusch R. Economics. 4th Edition. London, New York: McGraw Hill, 1994.
13. Layard R, Glaister S. Cost-benefit analysis. Cambridge, England: Cambridge University Press, 1994.
14. Jefferson T, Demichelli V, Mugford M. Elementary economic evaluation in health care. London, England: British Medical Journal Publishing Group, 1996.
15. Einarson TR, Arikan S, Sweeney S, Doyle J. A model to evaluate the cost-effectiveness of oral therapies in the management of patients with major depressive disorders. Clinical Therapeutics 1995;17:136-153.
16. Dunbar GC, Cohn JB, Fabre LF, et al. A comparison of SSRI antidepressants, Imipramine and placebo in depressed outpatients. British Journal of Psychiatry 1991; 159:394-398.
17. Broadhead WE, Blazer DG, George LK, Tse CK. Depression, disability days, and days lost from work in a prospective Epidemiological survey. Journal of the American Medical Association 1990;264:2524-2528.
18. Judd LL, Paulus MP, Wells KB, Rapaport MH. Socio-economic burden of subsyndromal depressive symptoms and major depression in a sample of the general population. American Journal of Psychiatry 1996;153:1411-1417.